Trials / Recruiting
RecruitingNCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- C4 Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemsidomide | dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle |
| DRUG | Dexamethasone | dosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle |
Timeline
- Start date
- 2026-02-18
- Primary completion
- 2030-03-01
- Completion
- 2030-03-01
- First posted
- 2025-12-16
- Last updated
- 2026-03-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07284758. Inclusion in this directory is not an endorsement.